TNFAIP8L2

Across TCGA pan-cancer cohorts, TNFAIP8L2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of TNFAIP8L2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TNFAIP8L2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TNFAIP8L2 is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

HNSC, CCRCC, and PDAC are the cancer types where TNFAIP8L2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TNFAIP8L2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	All	+0.470	<.001	12	view →
CCRCC	Female	II,III,IV	+0.870	<.001	11	view →
PDAC	Female	All	+0.679	<.001	4	view →
LSCC	Male	II,III,IV	−0.336	<.001	4	view →
LUAD	Male	All	−0.112	.028	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

TNFAIP8L2–HNSC

Open the HNSC breakdown →